Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Gilead price target raised to $175 from $171 at Morgan Stanley
11.04.2026 12:57
Morgan Stanley raised the firm’s price target on Gilead (GILD) to $175 from $171 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Pic
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
11.04.2026 01:54
Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and uneven reimbursement policies.
Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks
11.04.2026 00:24
Gilead Sciences is acquiring Tubulis GmbH in a deal worth up to $5b, its third major transaction in six weeks. The Tubulis deal brings next generation antibody drug conjugate technology and a pipeline of cancer therapies into Gilead’s oncology portfolio. Gilead has also acquired Arcellx and Ouro Medicines and exercised licensing options with Kymera Therapeutics and Cartography Biosciences to expand its cancer and autoimmune pipeline. For investors tracking NasdaqGS:GILD, these moves come as...
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
10.04.2026 04:43
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Gilead Sciences Inc. (NASDAQ:GILD) is one of the most profitable value stocks to buy right now. On April 7, Gilead Sciences announced its agreement to acquire Germany-based Tubulis GmbH for up to $5 billion. This transaction includes an […]
Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says
08.04.2026 15:06
Gilead Sciences (GILD) agreed to acquire Tubulis for $5 billion, its "third takeout" in six weeks as
Gilead Sciences Is Doubling Down On Acquisitions
08.04.2026 08:00
Gilead Sciences' recent acquisitions do not materially alter the investment thesis or valuation. Click here to see why GILD stock is a Hold.
Is Gilead Sciences (GILD) Among the Best Low Volatility Blue Chip Stocks to Buy Now?
08.04.2026 05:05
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Low Volatility Blue Chip Stocks to Buy Now. On April 7, Leerink reiterated an Outperform rating on Gilead Sciences, Inc. (NASDAQ:GILD), after the company announced a definitive agreement to acquire privately held Tubulis in a deal valued at up to $5 billion. The firm views […]
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
08.04.2026 00:06
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion April 7, 2026 4:30 PM EDTCompany...
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
07.04.2026 12:50
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.
Gilead to acquire Tubulis GmbH for up to $5 billion
07.04.2026 12:39
April 7 () - Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
07.04.2026 12:30
FOSTER CITY, Calif. & MUNICH, April 07, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead’s oncology pipeline, focused on addressing areas of high unmet need.
ValuEngine Weekly Market Summary And Commentary
07.04.2026 06:05
US equities continued their upward momentum over last week, with broad-based gains across major sectors led by tech, industrials, and small-caps. The energy sector was the notable exception.
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
01.04.2026 14:06
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
01.04.2026 11:05
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each offering a differentiated mechanism, commercial traction, or platform technology that a deep-pocketed acquirer would find difficult to replicate organically. Incyte Incyte (NASDAQ: INCY) ... 5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heat
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
31.03.2026 08:16
Gilead Sciences (NasdaqGS:GILD) has entered a definitive agreement to acquire Ouro Medicines, expanding into T cell engager therapies for autoimmune diseases. The company has also signed a collaboration agreement with Galapagos NV to advance T cell engager therapies. These moves affect Gilead's research pipeline and potential future treatment offerings. Gilead Sciences, trading at $136.34, has seen a 12.1% return year to date and a 24.9% return over the past year. Over 3 years, the stock...
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
31.03.2026 05:30
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks
28.03.2026 03:50
Gilead Sciences has experienced a significant valuation re-rating, now trading at 16-17x earnings after doubling from 2024 lows. Read why GILD stock is a hold.
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade)
27.03.2026 16:48
Gilead Sciences, Inc. now a Hold after a rally to ~$138. See valuation, HIV strength, Trodelvy upside, M&A risks, and $98â$209 range. Click for this GILD update.
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
27.03.2026 13:30
The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
27.03.2026 12:49
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.